abil
human
adenovirus
induc
strong
innat
adapt
immun
respons
make
power
adjuv
facilit
immun
respons
encod
antigen
recombin
adenovirus
shown
elicit
signific
immun
respons
bacteri
anthrax
plagu
viral
hepat
c
rabi
sar
tumourassoci
antigen
result
encourag
immun
eventu
develop
viru
capsid
protein
sever
reduc
immunogen
adenovirusbas
vaccin
mice
primat
human
problem
also
signific
sinc
larg
portion
western
world
mark
level
antiadenoviru
serotyp
antibodi
also
promin
region
subsaharan
africa
southeast
asia
mani
vaccin
need
thu
assess
impact
preexist
immun
immun
protect
altern
vaccin
strategi
may
need
success
use
mani
adenovirusbas
vaccin
sever
strategi
develop
address
preval
preexist
immun
gener
popul
increas
vector
dose
adopt
primeboost
regimen
order
overcom
preexist
immun
viru
common
approach
mix
enthusiasm
plan
howev
due
document
toxic
associ
high
dose
adenoviru
length
time
requir
primeboost
regimen
prime
could
suffici
seroswitch
use
recombin
adenovirus
construct
chimpanze
rare
human
serotyp
limit
exposur
rate
adenovirus
elicit
potent
immun
respons
minim
affect
preexist
immun
hexonchimer
adenovirus
also
avoid
neutral
approach
offer
promis
context
address
preexist
immun
requir
investig
respons
concern
regard
safeti
feasibl
largescal
product
coval
attach
polyethylen
glycol
incorpor
viru
polym
matrici
also
effect
protect
neutral
deliveri
vaccin
mucos
rout
also
circumv
effect
preexist
immun
induc
signific
immun
respons
encod
antigen
recombin
adenovirus
one
wellstudi
vector
current
develop
vaccin
ebola
viru
infect
first
protocol
ebola
vaccin
employ
primeboost
regimen
consist
nake
dna
express
either
ebola
glycoprotein
gp
nucleoprotein
np
recombin
express
ebola
gp
success
protect
nonhuman
primat
lethal
challeng
ebola
sinc
led
sever
phase
clinic
trial
compon
vaccin
administ
intramuscular
inject
date
two
report
describ
mucos
administr
ebola
vaccin
nasal
administr
recombin
human
parainfluenza
viru
type
vector
express
ebola
gp
andor
np
guinea
pig
rhesu
monkey
confer
complet
protect
lethal
challeng
ebola
previous
found
singl
dose
recombin
adenoviru
express
ebola
zair
gp
given
either
oral
nasal
rout
capabl
afford
protect
lethal
challeng
mice
mucos
immun
stimul
broad
prolong
cellmedi
immun
respons
system
mucos
compart
primari
object
studi
test
hypothesi
administr
ebola
vaccin
either
nasal
oral
rout
circumv
preexist
immun
confer
full
protect
upon
challeng
system
mucos
b
cell
respons
ebola
gp
assess
mice
preexist
immun
influenc
pegyl
vaccin
carrier
immun
respons
oral
immun
also
describ
adenoviru
vector
express
ebola
zair
glycoprotein
creat
clone
open
read
frame
orf
sequenc
glycoprotein
plasmid
pshuttl
adenox
express
system
bd
clonetech
palo
alto
ca
subsequ
insert
region
human
adenoviru
serotyp
genom
human
cytomegaloviru
cmv
promot
includ
adenox
express
system
use
drive
express
ebola
zair
glycoprotein
final
recombin
adenoviru
serotyp
construct
authent
final
product
confirm
sequenc
recombin
viru
rescu
transfect
linear
dna
cell
viru
sequenti
amplifi
largescal
infect
cell
purifi
affin
column
adenox
viru
purif
mega
kit
bd
clonetech
mountain
view
ca
accord
manufactur
instruct
genom
structur
vector
analyz
restrict
digest
isol
viral
dna
compar
origin
molecular
clone
particl
number
infect
vector
determin
standard
optic
densiti
read
immunodetect
hexon
protein
respect
follow
infect
cell
limit
dilut
vector
prepar
accord
recommend
manufactur
adenox
rapid
titer
kit
clontech
mountain
view
ca
purifi
viru
administ
steril
phosphat
buffer
salin
ph
particl
plaqu
form
unit
pfu
ratio
less
first
gener
recombin
adenoviru
express
ebola
zair
glycoprotein
prepar
purifi
describ
protein
content
viru
prepar
determin
use
biorad
dc
protein
assay
reagent
biorad
hercul
ca
bovin
serum
albumin
standard
micropl
format
accord
establish
protocol
monomethoxypoli
ethylen
glycol
activ
tresyl
chlorid
sigma
aldrich
st
loui
mo
ad
microgram
protein
present
coupl
reaction
perform
gentl
agit
reaction
stop
addit
llysin
excess
respect
amount
peg
ad
unreact
peg
excess
llysin
reaction
byproduct
remov
buffer
exchang
second
econopac
dispos
chromatographi
column
equilibr
mm
potassium
phosphatebuff
salin
ph
pegyl
prepar
administ
steril
potassium
phosphat
buffer
salin
ph
particl
plaqu
form
unit
pfu
ratio
less
determin
adenox
rapid
titer
kit
character
prepar
reveal
signific
chang
biophys
properti
viru
reaction
complet
pegdextran
partit
coeffici
peak
elut
time
capillari
electrophoresi
describ
previous
approxim
peg
molecul
associ
viru
particl
studi
outlin
determin
pegbiotin
assay
mice
immun
particl
recombin
viru
per
mous
either
intramuscular
inject
right
hindlimb
oral
gavag
use
oral
feed
needl
mm
dia
popper
son
inc
new
hyde
park
ny
nasal
immun
mice
anesthet
isofluran
anesthesia
achiev
particl
viru
slowli
deliv
bolu
nostril
use
standard
micropipett
gilson
middleton
wi
previous
describ
preexist
immun
adenoviru
serotyp
establish
inject
particl
adenoviru
express
betagalactosidas
adlacz
intramuscular
inject
right
hindlimb
day
prior
vaccin
protocol
document
activ
b
cell
viru
capsid
protein
elicit
humor
immun
time
vaccin
mice
averag
antiadenoviru
circul
nab
titer
fall
within
lower
rang
averag
valu
report
human
natur
infect
mice
challeng
intraperiton
inject
mouseadapt
ebola
viru
zair
strain
mazebov
steril
salin
challeng
anim
weigh
daili
day
monitor
clinic
sign
ebola
infect
use
approv
score
sheet
procedur
score
method
approv
institut
anim
care
committe
nation
microbiolog
laboratori
nml
public
health
agenc
canada
phac
accord
guidelin
canadian
council
anim
care
infecti
work
perform
biosafeti
level
facil
nml
phac
sera
collect
immun
mice
inactiv
minut
serial
dilut
sampl
etc
dmem
mix
equal
volum
recombin
ebola
zair
express
enhanc
green
fluoresc
protein
egfp
report
gene
zebovegfp
transduc
unitswel
accord
egfp
express
incub
minut
mixtur
ad
subconflu
cell
flatbottom
plate
incub
minut
room
temperatur
control
well
infect
equal
amount
either
zeboegfp
media
without
serum
contain
nonimmun
serum
dmem
supplement
fb
ad
well
plate
incub
hr
cell
subsequ
fix
buffer
formalin
h
examin
fluoresc
microscop
sampl
dilut
show
reduct
number
green
cell
compar
control
score
posit
neutral
antibodi
evalu
specif
level
igg
iga
antibodi
bronchoalveolar
lavag
bal
fluid
collect
situ
cathet
insert
proxim
trachea
flush
lower
airway
three
time
millilit
media
sigma
bal
anim
incub
minut
twofold
serial
dilut
ad
well
plate
precoat
overnight
ng
zebovlik
particl
per
well
incub
hr
goat
antimous
secondari
antibodi
conjug
horseradish
peroxidas
hrp
ad
plate
incub
one
addit
hour
abt
peroxidas
substrat
system
kpl
use
detect
data
collect
use
asi
uvm
elisa
plate
reader
isogen
life
scienc
infecti
vitro
work
perform
laboratori
nml
phac
preexist
immun
recombin
adenoviru
assess
determin
amount
neutral
antibodi
present
serum
accord
establish
method
brief
serum
incub
minut
dilut
dmem
twofold
increment
start
dilut
dilut
mix
aliquot
standard
stock
adenoviru
type
express
e
coli
betagalactosidas
pfu
incub
hour
appli
hela
cell
plate
cellswel
one
hundr
microlit
dmem
supplement
fb
ad
well
cell
incub
hour
neutral
antibodi
titer
calcul
highest
dilut
cell
stain
blue
visual
inspect
evalu
posit
cell
day
postimmun
splenocyt
harvest
cultur
hour
round
bottom
microtit
plate
dmem
supplement
fb
golgistop
bd
pharmingen
san
diego
ca
telrtfsi
peptid
carri
ebola
zair
gp
immunodomin
mhc
class
epitop
mice
haplotyp
use
stimul
concentr
control
cell
treat
either
unrel
peptid
peptid
wash
cell
stain
fitcanti
mous
antibodi
dilut
pharmingen
minut
cell
wash
permeabil
cytofixcytoperm
pharmingen
minut
wash
permwash
pharmingen
stain
peanti
mous
antibodi
dilut
pharmingen
buffer
minut
quantit
posit
cell
isol
splenocyt
mononuclear
cell
bronchioalveolar
lavag
bal
mesenter
lymph
node
mln
peyer
patch
pp
day
vaccin
perform
use
elispot
assay
elispot
mous
set
bd
pharmingen
san
diego
ca
accord
manufactur
instruct
briefli
elispot
plate
coat
antimous
captur
antibodi
cell
pool
mice
per
experiment
group
ad
microwel
along
telrtfsi
peptid
control
cell
incub
either
without
peptid
nonspecif
stimul
seb
ngml
incub
biotinyl
antimous
detect
antibodi
streptavidinhorseradish
peroxidas
antibodi
well
count
use
elispot
reader
aid
elispot
reader
system
cell
technolog
colombia
md
data
analyz
statist
signific
perform
unpair
test
twotail
p
valu
oneway
analysi
varianc
anova
appropri
differ
mean
raw
valu
among
treatment
group
consid
signific
p
effort
correl
marker
immun
protect
ebola
infect
mucos
immun
b
cell
specif
immun
respons
ebola
glycoprotein
analyz
mice
presenc
absenc
preexist
immun
pei
adenoviru
day
vaccin
first
gener
adenoviru
serotyp
vector
express
zair
ebola
glycoprotein
intracellular
stain
flow
cytometri
fac
reveal
ebola
glycoprotein
peptidespecif
activ
cell
measur
product
occur
anim
immun
nasal
rout
frequenc
figur
preexist
immun
induc
intramuscular
administr
recombin
express
nonrelev
antigen
betagalactosidas
adlacz
day
prior
vaccin
time
vaccin
mice
averag
antiadenoviru
circul
nab
titer
preexist
immun
significantli
alter
activ
cell
vaccin
given
intranas
inpei
p
oral
immun
lower
respons
ebola
glycoprotein
po
sampl
obtain
anim
preexist
immun
vaccin
manner
bare
posit
threshold
three
time
averag
background
level
obtain
anim
treat
irrelev
viru
adlacz
sampl
obtain
anim
immun
intramuscular
rout
im
contain
largest
popul
posit
cell
anim
treat
adlacz
vector
alon
adlaczcontrol
serv
neg
control
produc
cell
respons
ebola
glycoproteinspecif
peptid
b
cell
respons
ebola
glycoprotein
achiev
administr
vaccin
determin
incub
recombin
ebola
viru
zair
strain
express
green
fluoresc
protein
zebovegfp
serum
collect
day
vaccin
neutral
antibodi
nab
level
equival
reciproc
dilut
detect
anim
preexist
immun
intranas
immun
figur
sampl
anim
immun
oral
rout
contain
nab
level
equival
reciproc
dilut
wherea
antiebola
nab
could
detect
sampl
obtain
anim
immun
rout
preexist
immun
popei
nab
level
detect
sampl
obtain
mice
immun
intramuscular
rout
antiebola
nab
could
detect
sampl
mice
given
adlacz
vector
alon
adlacz
control
sinc
mucosa
often
primari
sight
exposur
longterm
local
immun
respons
ebola
viru
desir
provid
optim
protect
infect
context
cell
mediat
immun
respons
assess
elispot
variou
tissu
compart
specif
rout
immun
day
vaccin
number
activ
secret
mononuclear
cell
harvest
splenocyt
significantli
reduc
mice
vaccin
nasal
oral
compar
immun
intramuscular
inject
figur
contrast
sampl
obtain
spleen
anim
preexist
immun
immun
rout
contain
highest
number
activ
secret
cell
spotform
cell
sfc
million
mononuclear
cell
mnc
figur
although
approxim
lower
seen
naiv
anim
sfcmillion
mnc
figur
preexist
immun
also
significantli
reduc
number
cell
produc
anim
immun
im
sfcmillion
mnc
po
rout
sfcmillion
mnc
respect
seen
anim
im
po
figur
limit
number
activ
secret
mononuclear
cell
detect
splenocyt
anim
immun
adlacz
vector
sfcmillion
mnc
figur
preexist
immun
viru
adlacz
figur
signific
level
posit
cell
detect
bronchioalveolar
lavag
fluid
bal
intranas
immun
sfcmillion
mnc
figur
significantli
compromis
preexist
immun
adenoviru
sfcmillion
mnc
figur
limit
number
secret
cell
detect
bal
anim
immun
im
po
rout
sfcmillion
mnc
respect
figur
similar
seen
sampl
obtain
anim
given
adlacz
vector
neg
control
preexist
immun
adenoviru
reduc
cell
popul
valu
statist
signific
im
po
adlacz
sfcmillion
mnc
p
figur
posit
cell
found
mesenter
lymph
node
mln
peyer
patch
pp
sfcmillion
mnc
respect
oral
vaccin
adzgp
figur
preexist
immun
howev
reduc
product
cell
sfcmillion
mnc
mln
sfcmillion
mnc
pp
figur
nab
respons
also
monitor
bronchioalveolar
lavag
fluid
day
postvaccin
nab
zebovegfp
undetect
sampl
obtain
control
adlacz
im
immun
mice
wherea
level
reciproc
dilut
detect
bal
nasal
oral
vaccin
anim
respect
figur
preexist
immun
immun
nasal
rout
nab
level
nab
detect
mice
preexist
immun
immun
either
intramuscular
oral
rout
character
ebola
glycoproteinspecif
immunoglobulin
isotyp
obtain
bronchioalveolar
lavag
fluid
reveal
preexist
immun
correl
mark
decreas
product
igg
iga
antibodi
mice
immun
intramuscular
inject
figur
igg
iga
level
lowest
vaccin
oral
regardless
whether
preexist
immun
figur
immun
nasal
rout
induc
strong
igg
respons
reduc
averag
presenc
preexist
immun
strongest
iga
respons
detect
sampl
obtain
anim
given
vaccin
nasal
rout
iga
level
howev
also
reduc
mice
preexist
immun
direct
mean
evalu
vaccin
efficaci
mice
assess
protect
monitor
weight
loss
death
rate
lethal
challeng
ebola
therefor
mice
immun
particl
intramuscular
im
intranas
oral
po
rout
presenc
absenc
preexist
immun
time
vaccin
anim
averag
antiadenoviru
neutral
antibodi
titer
reciproc
dilut
mice
vaccin
intramuscular
inject
salin
vehicl
serv
control
complet
lethal
follow
challeng
mouseadapt
ebola
viru
twentyeight
day
vaccin
anim
challeng
mouseadapt
zebov
mice
immun
nasal
rout
surviv
lethal
challeng
figur
evid
earli
day
challeng
control
mice
immun
rout
began
lose
weight
figur
eventu
expir
day
postchalleng
figur
data
shown
clariti
contrast
mice
given
vaccin
surviv
challeng
regardless
rout
administr
studi
outlin
strongli
suggest
intranas
immun
success
afford
protect
ebola
viru
absenc
presenc
preexist
immun
also
clear
addit
strategi
need
improv
vaccin
either
oral
intramuscular
rout
presenc
preexist
immun
coval
attach
activ
monomethoxypolyethylen
glycol
protein
capsid
vector
evalu
potenti
way
improv
immun
respons
oral
vaccin
base
upon
previou
observ
hypothes
modif
would
protect
viru
neutral
immun
sera
improv
surviv
gastrointestin
tract
frequenc
ebola
glycoprotein
peptidespecif
activ
posit
cell
signific
anim
given
pegyl
viru
respect
given
unmodifi
viru
p
figur
similar
result
also
seen
presenc
preexist
immun
either
treatment
group
pegyl
vaccin
unmodifi
vaccin
contrast
nab
level
equival
reciproc
dilut
detect
anim
given
pegyl
vaccin
figur
sampl
obtain
anim
given
unmodifi
viru
level
reciproc
dilut
anim
immun
adenoviru
treat
pegyl
prepar
also
abl
produc
detect
level
nab
reciproc
dilut
wherea
nab
found
sera
mice
given
unmodifi
vector
oral
character
ebola
glycoproteinspecif
ig
isotyp
reveal
pegyl
vector
could
possibl
stimul
product
igg
presenc
absenc
preexist
immun
respect
level
found
anim
given
unmodifi
vector
figur
modif
viru
induc
slight
increas
iga
presenc
preexist
immun
respect
seen
anim
given
unmodifi
viru
vaccin
figur
preexist
immun
vaccinepei
despit
anim
preexist
immun
adenoviru
immun
pegyl
vaccin
oral
surviv
challeng
zebov
mortal
rate
high
ebola
infect
occur
larg
direct
contact
blood
tissu
skin
patient
mucos
exposur
date
effort
made
focu
mucosa
primari
sight
exposur
ebola
viru
prime
particip
host
defens
vaccin
surpris
given
pulmonari
nasal
oral
immun
system
compris
mucosalassoci
lymphoid
tissu
malt
respons
product
approxim
immunocyt
mucos
immun
often
first
line
defens
pathogen
come
contact
suscept
host
mani
studi
rodent
indic
system
immun
produc
strong
antivir
system
respons
mucos
vaccin
stimul
mucos
system
immun
system
confer
longterm
immunolog
memori
given
pathogen
despit
fact
magnitud
respons
often
report
somewhat
reduc
found
case
studi
outlin
sinc
system
cellular
respons
neutral
antibodi
level
ebola
zair
gp
consist
lower
follow
nasal
oral
vaccin
mucos
vaccin
howev
gener
signific
cellular
antibodi
respons
peripheri
bal
mln
peyer
patch
singl
intranas
immun
confer
protect
even
presenc
preexist
immun
administr
recombin
adenovirusbas
vaccin
mucosa
also
confer
suffici
protect
challeng
varieti
pathogen
presenc
preexist
immun
vaccin
carrier
mice
preclin
model
diseas
serv
basi
present
studi
singl
intranas
dose
recombin
vaccin
express
zair
ebola
glycoprotein
confer
protect
mice
preexist
immun
despit
fact
strength
immun
respons
gener
rout
administr
quantit
lower
seen
anim
vaccin
intramuscular
inject
also
import
note
preexist
immun
induc
intramuscular
inject
sever
compromis
cellmedi
respons
either
system
mucos
level
anim
level
antiebola
gp
antibodi
circul
lung
also
significantli
compromis
preexist
immun
adenoviru
result
suggest
intranas
vaccin
adbas
vaccin
inde
promis
strategi
overcom
preexist
immun
one
might
wonder
accur
result
translat
natur
exposur
wild
type
viru
via
respiratori
tract
somewhat
difficult
establish
mous
model
sinc
abil
wildtyp
adenoviru
replic
limit
addit
amount
neutral
antibodi
present
nasal
caviti
gener
popul
preexist
immun
adenoviru
assess
degre
serum
neutral
antibodi
make
difficult
set
rel
paramet
one
target
preclin
anim
model
lack
data
may
due
invas
natur
techniqu
acquir
sampl
andor
fact
antibodi
level
mucosa
individu
establish
preexist
immun
adenoviru
type
quit
low
transient
contrast
system
level
antiadenoviru
neutral
antibodi
quit
robust
persist
time
unreport
observ
thu
studi
decid
induc
preexist
immun
adenoviru
intramuscular
inject
dose
shown
induc
product
system
neutral
antibodi
level
mostli
report
human
document
preexist
immun
addit
studi
design
assess
amount
neutral
antibodi
lung
time
intranas
administr
vari
dose
current
underway
effort
defin
stringent
condit
preexist
immun
establish
experiment
test
data
obtain
anim
vaccin
oral
rout
provid
sever
insight
immunolog
requir
protect
ebola
mous
model
immun
rout
induc
quantit
lower
b
cell
mediat
immun
respons
ebola
glycoprotein
respect
achiev
either
intramuscular
intranas
immun
despit
everi
anim
immun
singl
oral
dose
adzgp
surviv
challeng
give
better
precis
minim
threshold
immun
requir
achiev
protect
seen
intranas
immun
cellmedi
respons
compromis
preexist
immun
day
oral
vaccin
number
secret
cell
mucos
system
compart
anim
day
howev
significantli
reduc
preexist
immun
possibl
peak
cell
respons
day
reflect
extent
preexist
immun
decreas
cell
respons
altern
also
possibl
elispot
assay
could
detect
subtl
variat
flow
cytometeri
could
monitor
accur
due
differ
sensit
assay
neutral
antibodi
detect
serum
anim
preexist
immun
given
singl
oral
dose
vaccin
importantli
none
anim
surviv
challeng
mous
adapt
ebola
attempt
improv
immunogen
adenovirusbas
vaccin
protect
harsh
environ
gastrointestin
tract
neutral
antiadenoviru
antibodi
pegyl
interestingli
tcell
mediat
immun
respons
significantli
reduc
antibodi
level
increas
anim
given
singl
oral
dose
pegyl
vaccin
respect
seen
anim
given
dose
unmodifi
shown
modif
viru
capsid
pegyl
significantli
dampen
tcell
mediat
immun
respons
viru
stimul
antibodi
respons
secret
antigen
taken
togeth
data
support
notion
exposit
viru
capsid
protein
facilit
immun
respons
encod
antigen
optim
pegyl
chemistri
andor
densiti
adenovirusbas
vaccin
promot
strengthen
protect
immun
respons
follow
oral
immun
current
underway
deliveri
recombin
adenovir
vaccin
either
nasal
intestin
mucosa
attract
vaccin
strategi
mani
reason
vaccin
administ
manner
offer
improv
safeti
respect
diseas
transmiss
needlestick
injuri
among
health
care
worker
signific
issu
concern
develop
countri
demand
mani
vaccin
high
mucos
administr
vaccin
reduc
pain
associ
vaccin
elimin
need
special
train
program
larg
vaccin
campaign
make
selfadministr
vaccin
possibl
rout
administr
may
also
significantli
reduc
system
toxic
associ
recombin
adenoviru
despit
fact
shown
nasal
immun
recombin
adenovirusbas
vaccin
facilit
transloc
viru
central
nervou
system
even
though
test
virusbas
vaccin
influenza
report
similar
find
current
use
clinic
studi
design
fulli
assess
toxicolog
profil
adenoviru
vaccin
nasal
administr
also
current
underway
shown
nasal
immun
vaccin
induc
longterm
protect
immun
respons
ebola
viru
mous
model
imped
preexist
immun
adenoviru
serotyp
result
extrem
encourag
character
immun
respons
encod
antigen
adenoviru
vector
larger
clinic
relev
anim
model
vital
understand
biolog
ad
vaccin
develop
effect
ebola
vaccin
suitabl
popul
differ
requir
issu
preexist
immun
must
also
adequ
address
order
develop
effici
recombin
adenovirusbas
vaccin
major
literatur
suggest
preexist
immun
significantli
hamper
effect
use
vaccin
carrier
investig
report
preexist
immun
interfer
potenc
recombin
vaccin
preclin
model
diseas
human
thu
addit
studi
identifi
clinic
relev
condit
test
adbas
vaccin
candid
necessari
assess
full
impact
preexist
immun
vaccin
potenc
includ
differ
compart
better
defin
role
preexist
immun
vaccineinduc
immun
understand
individu
previous
expos
adenoviru
respond
immun
regimen
